HIF1A and prostate cancer: It was reported [34–36] that increased levels of HIF-1 or HIF-2 were correlated with adverse prognosis in breast, cervical, endometrial, colorectal, NSCLC, ovarian, rectal, pancreatic and prostate cancers.